AbCellera Biologics (NASDAQ:ABCL) Issues Earnings Results, Beats Estimates By $0.04 EPS

AbCellera Biologics (NASDAQ:ABCL) released its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04, FiscalAI reports. The firm had revenue of $10.64 million for the quarter, compared to the consensus estimate of $8.41 million. AbCellera Biologics had a negative return on equity of 15.88% and a negative net margin of 218.54%. During the same quarter in the prior year, the company posted ($0.19) earnings per share.

Here are the key takeaways from AbCellera Biologics’ conference call:

• AbCellera reported strong four-week Phase II results for ABCL635, with an 83% reduction in daily moderate-to-severe hot flashes versus 33% on placebo, and no clear gastrointestinal or liver-toxicity signal. The company cautioned that the study assessed a single dose and that comparisons with other treatments are cross-trial.
• The company plans to advance ABCL635 into late-stage development in 2027 and expects to release 12-week and open-label extension data in early 2027. It also plans to study the drug for treatment-related hot flashes in breast and prostate cancer patients, while a longer-acting follow-on, ABCL992, entered IND-enabling work.
• After completing an oversubscribed $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and over $890 million in available liquidity including committed government funding. Management said it has funding for at least three years of pipeline investment.
• AbCellera added three programs—ABCL992, an oncology program, and an ion-channel-targeting antibody—and said ABCL688 and ABCL386 remain in IND-enabling work, with both potentially entering clinical trials in 2027.
• Despite favorable Phase I tolerability and pharmacokinetic results for ABCL575, AbCellera does not plan to advance it beyond Phase I, citing setbacks for other drugs targeting the OX40/OX40L pathway.

AbCellera Biologics Stock Performance

ABCL opened at $12.46 on Wednesday. The company has a market cap of $3.82 billion, a PE ratio of -25.96 and a beta of 1.59. The stock has a 50-day moving average of $12.32 and a 200-day moving average of $7.12. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $15.02.

Key Stories Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Quarterly results exceeded estimates. AbCellera reported a Q3 loss of $0.13 per share, narrower than analysts’ expected $0.17 loss, and revenue of $10.64 million versus an $8.41 million estimate. The loss also improved from $0.19 per share a year earlier. AbCellera Reports Q3 2026 Business Results
• Positive Sentiment: Stifel Nicolaus raised its price target to $14 from $9 and maintained a Buy rating, citing potential upside from the cited $12.46 share price. Stifel Nicolaus stock recommendations
• Neutral Sentiment: Short-interest figures appear inconsistent. The report calls the change significant but lists short interest at zero shares and a 0.0-day ratio, so it does not provide a clear short-selling signal.
• Negative Sentiment: AbCellera is still unprofitable. Despite beating estimates, the company reported a quarterly loss and a negative net margin, underscoring ongoing profitability risk.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ABCL. Cantor Fitzgerald lifted their target price on shares of AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Truist Financial boosted their target price on shares of AbCellera Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Stifel Nicolaus increased their price target on shares of AbCellera Biologics from $9.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday. Jefferies Financial Group started coverage on shares of AbCellera Biologics in a research note on Friday, October 30th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.33.

AbCellera Biologics Company Profile

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.